PerCP/Cyanine5.5 anti-mouse CD4 Antibody

Pricing & Availability
Clone
RM4-5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2a, κ
RM4-5_PerCPCy55_CD4_Antibody_101618
C57BL/6 mouse splenocytes stained with CD3e APC and CD4 (clone RM4-5) PerCP/Cyanine5.5 (left), or rat IgG2a, κ PerCP/Cyanine5.5 isotype (right).
  • RM4-5_PerCPCy55_CD4_Antibody_101618
    C57BL/6 mouse splenocytes stained with CD3e APC and CD4 (clone RM4-5) PerCP/Cyanine5.5 (left), or rat IgG2a, κ PerCP/Cyanine5.5 isotype (right).
Compare all formats See PerCP/Cyanine5.5 spectral data
Cat # Size Price Quantity Check Availability
100539 25 µg $103.00
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100540 100 µg $283.00
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes and a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a co-receptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosine kinase lck.

Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
BALB/c mouse thymocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD4 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is = 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Application Notes

The RM4-5 antibody blocks the binding of GK1.5 antibody and H129.19 antibody to CD4+ T cells, but not RM4-4 antibody. Additional reported applications (for the relevant formats) include: blocking of ligand binding, in vivo depletion of CD4+ cells1, and immunohistochemistry of acetone-fixed frozen tissue sections2,3,11 and paraffin-embedded sections11. Clone RM4-5 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. Instead, acetone frozen or zinc-fixed paraffin sections are recommended. The Ultra-LEAF™ Purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100575 and 100576).

Application References

(PubMed link indicates BioLegend citation)
  1. Kruisbeek AM. 1991. In Curr. Protocols Immunol. pp. 4.1.1-4.1.5. (Block, Deplete)
  2. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  3. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045.
  4. Muraille E, et al. 2003. Infect. Immun. 71:2704. (IHC)
  5. León-Ponte M, et al. 2007. Blood 109:3139. (FC)
  6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370. (FC)
  7. Matsumoto M, et al. 2007.J. Immunol.178:2499. PubMed
  8. Shigeta A, et al. 2008. Blood 112:4915. PubMed
  9. Zaborsky N, et al. 2010. J. Immunol. 184:725. PubMed
  10. Rodrigues-Manzanet R, et al. 2010. P. Natl Acad Sci USA 107:8706. PubMed
  11. Whiteland JL, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)
Product Citations
  1. Hajnik RL, et al. 2022. Sci Transl Med. 14:eabq1945. PubMed
  2. Cai Z, et al. 2023. Adv Sci (Weinh). 10:e2207155. PubMed
  3. Hao H, et al. 2023. Nat Biomed Eng. . PubMed
  4. Florian DC, et al. 2023. Cancer Res Commun. 3:223. PubMed
  5. Liu KY, et al. 2023. Environ Health Perspect. 131:37014. PubMed
  6. Zeng S, et al. 2023. Front Oncol. 13:1171926. PubMed
  7. Zheng J, et al. 2022. Front Pharmacol. 13:866228. PubMed
  8. Lee SA, et al. 2020. J Immunol. 204:586. PubMed
  9. Tian WJ, et al. 2021. Clin Exp Pharmacol Physiol. 48:902. PubMed
  10. Pohlmeier L, et al. 2021. Allergy. 76:2030. PubMed
  11. van Dierendonck XAMH, et al. 2022. Proc Natl Acad Sci U S A. 119:e2114739119. PubMed
  12. Martin-Martin I, et al. 2022. Cell Rep. 39:110648. PubMed
  13. Serra M, et al. 2022. Cell Mol Gastroenterol Hepatol. 14:609. PubMed
  14. Chen Q, et al. 2022. Cell Rep. 39:110990. PubMed
  15. Balood M, et al. 2022. Nature. 611:405. PubMed
  16. Briukhovetska D, et al. 2023. Immunity. 56:143. PubMed
  17. Shen JZ, et al. 2022. Mol Cell. 82:1123. PubMed
  18. Delvecchio FR, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1543. PubMed
  19. Kim TJ, et al. 2019. Nat Commun. 10:3258. PubMed
  20. Baldwin SL, et al. 2021. PLoS One. 16:e0247990. PubMed
  21. Hewitson JP, et al. 2020. J Immunol. 204:2949. PubMed
  22. Li JY, et al. 2020. J Clin Invest. 130:1767. PubMed
  23. Schmidleithner L et al. 2019. Immunity. 50(5):1232-1248 . PubMed
  24. Tyagi AM et al. 2018. Immunity. 49(6):1116-1131 . PubMed
  25. Böttcher JP, et al. 2018. Cell. 172:1022. PubMed
  26. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  27. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  28. Zhang F, et al. 2019. Nat Commun. 10:3974. PubMed
  29. Castiglioni A, et al. 2015. PLoS One. 10:128094. PubMed
  30. Isakova-Sivak I, et al. 2020. Vaccines (Basel). 8:00. PubMed
  31. Yu M, et al. 2021. J Clin Invest. 131:. PubMed
  32. Kitano M, et al. 2016. Proc Natl Acad Sci U S A. 113: 1044 - 1049. PubMed
  33. Sharma S, et al. 2015. J Immunol. 194:5529. PubMed
  34. Solanki A, et al. 2018. Development. 145. PubMed
  35. Willingham SB, et al. 2018. Cancer Immunol Res. 6:1136. PubMed
  36. Voisin M, et al. 2021. Commun Biol. 4:420. PubMed
  37. Leonard JD et al. 2017. Immunity. 47(1):107-117 . PubMed
  38. Luo Y et al. 2019. Cell reports. 26(7):1869-1879 . PubMed
  39. Miska J et al. 2019. Cell reports. 27(1):226-237 . PubMed
  40. Tuganbaev T, et al. 2020. Cell. 182(6):1441-1459.e21. PubMed
  41. JI B, et al. 2016. Cell Death Differ. 23:759-75. PubMed
  42. Burrack K, et al. 2015. PLoS Pathog. 11: e1005191. PubMed
  43. Yue X, et al. 2019. Nat Commun. 10:2011. PubMed
  44. Alikhanyan K, et al. 2021. Cancers (Basel). 13:. PubMed
  45. Drees J, et al. 2015. Anticancer Res. 35:843. PubMed
  46. Tyagi AM, et al. 2021. eLife. 10:00. PubMed
  47. Reinfeld BI, et al. 2021. Nature. 593:282. PubMed
  48. Vogel AB, et al. 2021. Nature. 592:283. PubMed
  49. Gniadek TJ, et al. 2020. J Immunother. 43:217. PubMed
  50. Alikhanyan K, et al. 2020. Immun Inflamm Dis. 8:181. PubMed
  51. Alameh MG, et al. 2021. Immunity. 54:2877. PubMed
  52. Bosnjak B, et al. 2021. Front Immunol. 12:772240. PubMed
  53. White C, et al. 2015. J Immunol. 194:697. PubMed
  54. Shen JZ, et al. 2020. Cell. 184(2):352-369.e23. PubMed
  55. Li X, et al. 2020. Nat Commun. 4.877777778. PubMed
  56. Ishikawa E, et al. 2016. Nat Commun. 7: 12756. PubMed
  57. Lim S, et al. 2016. PLoS One. 11: 0155689. PubMed
  58. Duan H et al. 2018. Immunity. 49(2):301-311 . PubMed
  59. Xu Q, et al. 2021. Theranostics. 11:1937. PubMed
  60. Shiozawa S, et al. 2022. iScience. 25:103537. PubMed
  61. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  62. Muri J, et al. 2020. eLife. 9:e53627.. PubMed
  63. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  64. Lebrun A, et al. 2015. J Immunol. 195: 4358 - 4368. PubMed
  65. Chen X, et al. 2019. Med Sci Monit. 25:5389. PubMed
  66. Nagashima H et al. 2019. Immunity. 51(4):682-695 . PubMed
  67. Yue X, et al. 2021. EMBO Rep. 22:e52716. PubMed
  68. Lainé A, et al. 2021. Nat Commun. 12:6228. PubMed
  69. Yasuma K, et al. 2016. PLoS Pathog. 12: 1005372. PubMed
  70. Chen X, et al. 2021. Immunity. 54(2):324-339.e8. PubMed
  71. Sun X, et al. 2017. Microbes Infect. 10.1016/j.micinf.2017.08.007. PubMed
  72. Shaikh H, et al. 2021. Front Immunol. 12:689896. PubMed
  73. Ren S, et al. 2022. Int J Biol Sci. 18:166. PubMed
  74. Hoechst B, et al. 2016. J Immunol. 195:1517-1523. PubMed
  75. Matsumoto M, et al. 2021. Cell Host Microbe. 29(6):930-940.e4. PubMed
  76. Zeng J, et al. 2020. Int J Biol Sci. 1.939583333. PubMed
  77. Aalipour A, et al. 2020. Mol Ther Oncolytics. 17:232. PubMed
  78. Kunishita Y, et al. 2020. Front Immunol. 11:98. PubMed
  79. Silva HM, et al. 2019. J Exp Med. 216:786. PubMed
  80. Chen X, et al. 2022. STAR Protoc. 3:101180. PubMed
  81. Lederer K, et al. 2020. Immunity. 53(6):1281-1295.e5. PubMed
  82. Rossnagl S, et al. 2016. PLoS Biol. 14: 1002562. PubMed
  83. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  84. Tan DQ, et al. 2019. Cell Rep. 26:2316. PubMed
  85. Yang F, et al. 2021. Nat Commun. 12:3424. PubMed
RRID
AB_893326 (BioLegend Cat. No. 100539)
AB_893326 (BioLegend Cat. No. 100540)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org
Go To Top Version: 3    Revision Date: 01/29/2013

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Login/Register
Forgot your password? Reset Password
Request an Account